The pharmacological chaperone effect of N-octyl-β-valienamine on human mutant acid β-glucosidases

Blood Cells, Molecules, and Diseases

Volumn 44, Issue 1, 2010, Pages 48-54

  Luan, Zhuo ^a   Li, Linjing ^a   Ninomiya, Haruaki ^a   Ohno, Kousaku ^a   Ogawa, Seiichiro ^b   Kubo, Takatoshi ^c   Iida, Masami ^c   Suzuki, Yoshiyuki ^d  

^a TOTTORI UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c SEIKAGAKU CORPORATION   (Japan)

^d INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Glucosidase; Chaperone therapy; Gaucher's disease; N octyl valienamine

Indexed keywords

GLUCOSYLCERAMIDASE; GLYCOSIDASE INHIBITOR; N OCTYL BETA VALIENAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STRAIN COS1; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; GAUCHER DISEASE; GENE MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN FIBROBLAST;

ANIMALS; CATALYTIC DOMAIN; CELL LINE; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; COS CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GLUCOSYLCERAMIDASE; HEXOSAMINES; HUMANS; HYDROGEN-ION CONCENTRATION; LYSOSOMES; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; MUTATION; PROTEIN STRUCTURE, TERTIARY; TIME FACTORS; TRANSFECTION;

EID: 72649095206     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2009.10.003     Document Type: Article

References (39)

1. Beutler E., and Grabowski G.A. Gaucher disease. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease. ed 8th (2001), McGraw-Hill, New York 2641-2670
2. Butters T.D. Gaucher disease. Curr. Opin. Chem. Biol. 11 (2007) 412-418
3. Barton N.W., Brady R.O., Dambrosia J.M., Di Bisceglie A.M., Doppelt S.H., Hill S.C., Mankin H.J., Murray G.J., Parker R.I., and Argoff C.E. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 324 (1991) 1464-1470
4. Cox T., Lachmann R., Hollak C., Aerts J., van Weely S., Hrebicek M., Platt F., Butters T., Dwek R., and Moyses C. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT918) to decrease substrate biosynthesis. Lancet 355 (2000) 1481-1485
5. Grabowski G.A., Leslie N., and Wenstrup R. Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev. 12 (1998) 115-133
6. Platt F.M., Jeyakumar M., Andersson U., Priestman D.A., Dwek R.A., and Butters T.D. Inhibition of substrate synthesis as a strategy for glycolipids lysosomal storage disease therapy. J. Inherit. Metab. Dis. 24 (2001) 275-290
7. Schiffmann R., Heyes M.P., Aerts J.M., Dambrosia J.M., Patterson M.C., DeGraba T., Parker C.C., Zirzow G.C., Oliver K., and Tedeschi G. Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease. Ann. Neurol. 42 (1997) 613-621
8. Prows C.A., Sanchez N., Daugherty C., and Grabowski G.A. Gaucher disease: enzyme therapy in the acute neuronopathic variant. Am. J. Med. Genet. 71 (1997) 16-21
9. Aoki M., Takahashi Y., Miwa Y., Iida S., Sukegawa K., Horai T., Orii T., and Kondo N. Improvement of neurological symptoms by enzyme replacement therapy for Gaucher disease type IIIb. Eur. J. Pediatr. 160 (2001) 63-64
10. Aerts J.M., Hollak C.E., Boot R.G., Groener J.E., and Maas M. Substrate reduction therapy of glycosphingolipid storage disorders. Inherit. Metab. Dis. 29 (2006) 449-456
11. Ron I., and Horowitz M. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum. Mol. Genet. 14 (2005) 2387-2398
12. Ogawa S., Ashiura M., Uchida C., Watanabe S., Yamazaki C., Yamagishi K., and Inokuchi J. Synthesis of potent β-d-glucocerebrosidase inhibitors: N-alkyl-β-valienamines. Bioorg. Med. Chem. Lett. 6 (1996) 929-932
13. Lin H., Sugimoto Y., Ohsaki Y., Ninomiya H., Oka A., Taniguchi M., Ida H., Eto Y., Ogawa S., Matsuzaki Y., Sawa M., Inoue T., Higaki K., Nanba E., Ohno K., and Suzuki Y. N-octyl-beta-valienamine up-regulates activity of F213I mutant beta-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease. Biochim. Biophys. Acta 1689 (2004) 219-228
14. Lei K., Ninomiya H., Suzuki M., Inoue T., Sawa M., Iida M., Ida H., Eto Y., Ogawa S., and Ohno K. Enzyme enhancement activity of N-octyl-beta-valienamine on beta-glucosidase mutants associated with Gaucher disease. Biochim. Biophys. Acta 1772 (2007) 587-596
15. Dvir H., Harel M., McCarthy A.A., Toker L., Silman I., Futerman A.H., and Sussman J.L. X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep. 4 (2003) 704-709
16. Beutler E., and Gelbart T. Glucocerebrosidase (Gaucher disease). Hum. Mutat. 8 (1996) 207-213
17. Kawame H., Hasegawa Y., Eto Y., and Maekawa K. Rapid identification of mutations in the glucocerebrosidase gene of Gaucher disease patients by analysis of single-strand conformation polymorphisms. Hum. Genet. 90 (1992) 294-296
18. Beutler E., and Gelbart T. Hematologically important mutations: Gaucher disease. Blood Cells Mol. Dis. 24 (1998) 2-8
19. Beutler E., Gelbart T., Balicki D., Demina A., Adusumalli J., Elsas L., Grinzaid K.A., Gitzelmann R., Superti-Furga A., Kattamis C., and Liou B.B. Gaucher disease: four families with previously undescribed mutations. Proc. Assoc. Am. Physicians 108 (1996) 179--184
20. Cormand B., Grinberg D., Gort L., Chabás A., and Vilageliu L. Molecular analysis and clinical findings in the Spanish Gaucher disease population: putative haplotype of the N370S ancestral chromosome. Hum. Mutat. 11 (1998) 295-305
21. Seeman P.J., Finckh U., Höppner J., Lakner V., Liebisch I., Grau G., and Rolfs A. Two new missense mutations in a non-Jewish Caucasian family with type 3 Gaucher disease. Neurology 46 (1996) 1102-1107
22. Eyal N., Wilder S., and Horowitz M. Prevalent and rare mutations among Gaucher patients. Gene 96 (1990) 277-283
23. Choy F.Y., Humphries M.L., and Ben-Yoseph Y. Gaucher type 2 disease: identification of a novel transversion mutation in a French-Irish patient. Am. J. Med. Genet. 78 (1998) 92-93
24. Filocamo M., Bonuccelli G., Mazzotti R., Corsolini F., Stroppiano M., Regis S., and Gatti R. Somatic mosaicism in a patient with Gaucher disease type 2: implication for genetic counseling and thtic decision-making. Blood Cells Mol. Dis. 26 (2000) 611-612
25. Matsuda J., Suzuki O., Oshima A., Yamamoto Y., Noguchi A., Takimoto K., Itoh M., Matsuzaki Y., Yasuda Y., Ogawa S., Sakata Y., Nanba E., Higaki K., Ogawa Y., Tominaga L., Ohno K., Iwasaki H., Watanabe H., Brady R.O., and Suzuki Y. Chemical chaperone therapy for brain pathology in GM1-gangliosidosis. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15912-15917
26. Vaccaro A.M., Muscillo M., Tatti M., Salvioli R., Gallozzi E., and Suzuki K. Effect of a heat-stable factor in human placenta on glucosylceramidase, glucosylsphingosine glucosyl hydrolase, and acid beta-glucosidase activities. Clin. Biochem. 20 (1987) 429-433
27. Ichisaka S., Ohno K., Yuasa I., Nanba E., Sakuraba H., and Suzuki Y. Increased expression of β-hexosaminidase α chain in cultured skin fibroblasts from patients with carbohydrate-deficient glycoprotein syndrome type I. Brain Dev. 20 (1998) 302-306
28. Suzuki Y., Tsuji A., Omura K., Nakamura G., Awa S., Kroos M., and Reuser A.J. Km mutant of acid α-glucosidase in a case of cardiomyopathy without signs of skeletal muscle involvement. Clin. Genet. 33 (1988) 376-385
29. Sawkar A.R., Adamski-Werner S.L., Cheng W.C., Wong C.H., Beutler E., Zimmer K.P., and Kelly J.W. Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem. Biol. 12 (2005) 1235-1244
30. Kawasaki K., Nishio A., Nakamura H., Uchida K., Fukui T., Ohana M., Yoshizawa H., Ohashi S., Tamaki H., Matsuura M., Asada M., Nishi T., Nakase H., Toyokuni S., Liu W., Yodoi J., Okazaki K., and Chiba T. Helicobacter felis-induced gastritis was suppressed in mice overexpressing thioredoxin-1. Lab. Invest 85 (2005) 1104-1117
31. Steet R.A., Chung S., Wustman B., Powe A., Do H., and Kornfeld S.A. The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 13813-13818
32. Zheng W., Padia J., Urban D.J., Jadhav A., Goker-Alpan O., Simeonov A., Goldin E., Auld D., LaMarca M.E., Inglese J., Austin C.P., and Sidransky E. Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 13192-13197
33. Chang H.H., Asano N., Ishii S., Ichikawa Y., and Fan J.Q. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients. FEBS J. 273 (2006) 4082-4092
34. Iwasaki H., Watanabe H., Iida M., Ogawa S., Tabe M., Higaki K., Nanba E., and Suzuki Y. Fibroblast screening for chaperone therapy in β-galactosidosis. Brain Dev. 28 (2006) 482-486
35. Fan J.Q., Ishii S., Asano N., and Suzuki Y. Accelerated transport and maturation of lysosomeal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat. Med. 5 (1999) 112-115
36. Suzuki Y., Ichinomiya S., Kurosawa M., Ohkubo M., Watanabe H., Iwasaki H., Matsuda J., Noguchi Y., Takimoto K., and Itoh M. Chemical chaperone therapy: clinical effect in murine G(M1)-gangliosidosis. Ann. Neurol. 62 (2007) 671-675
37. Sawkar A.R., Cheng W.C., Beutler E., Wong C.H., Balch W.E., and Kelly J.W. Chemical chaperones increase the cellular activity of N370S β-glucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 15428-15433
38. Tropak M.B., Reid S.P., Guiral M., Withers S.G., and Mahuran D. Pharmacological enhancement of β-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff patients. J. Biol. Chem. 279 (2004) 13478-13487
39. Parenti G., Zuppaldi A., Gabriela Pittis M., Rosaria Tuzzi M., Annunziata I., Meroni G., Porto C., Donaudy F., Rossi B., and Rossi M. Pharmacological enhancement of mutated α-glucosidase activity in fibroblasts from patients with Pompe disease. Mol. Ther. 15 (2007) 508-514